Onconova Therapeutics, Inc. to Present Corporate Updates at Upcoming Investor Conferences
September 07 2016 - 7:01AM
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer, today announced that Ramesh Kumar,
Ph.D., President and Chief Executive Officer, will present company
updates at the 23rd Annual BioCentury NewsMakers in the Biotech
Industry Conference and the Rodman & Renshaw 18th Annual Global
Investment Conference.
Details for the presentations and webcast
information are below:
23rd Annual BioCentury NewsMakers in the
Biotech Industry
Conference Date:
9/9/2016 Time: 3:30 PM ET Location: Millennium Broadway Hotel
and Conference Center, New York, NY Webcast:
http://wsw.com/webcast/biocentury3/ontx
Rodman and Renshaw 18th Annual Global Investment
Conference Date:
9/13/2016
Time: 5:30 PM ET Location: Lotte New York Palace Hotel, New York,
NY Webcast: http://wsw.com/webcast/rrshq26/ontx
Live and archived versions of the presentations
will also be available by visiting "Events & Presentations" in
the Investors and Media section of the Company's website
at www.onconova.com.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a Phase 3
clinical-stage biopharmaceutical company focused on discovering and
developing novel products to treat cancer. Onconova's clinical and
pre-clinical stage drug development candidates are derived from its
extensive chemical library and are designed to work against
specific cellular pathways that are important in cancer cells,
while causing minimal damage to normal cells. The Company’s most
advanced product candidate, rigosertib, is a small molecule
inhibitor of cellular signaling and acts as a RAS mimetic. These
effects of rigosertib appear to be mediated by direct binding of
the compound to the RAS-binding domain (RBD) found in many RAS
effector proteins, including the Raf kinases and PI3K.
Rigosertib is protected by issued patents (earliest expiry in 2026)
and has been awarded Orphan Designation for MDS in the United
States, Europe and Japan. In addition to rigosertib, two
other candidates are clinical stage, and several candidates are in
pre-clinical stages. For more information, please
visit http://www.onconova.com.
Forward Looking Statements
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements relate to future events or Onconova
Therapeutics, Inc.'s future operations, clinical development of
Onconova's product candidates and presentation of data with respect
thereto, regulatory approvals, expectations regarding the
sufficiency of Onconova's cash and other resources to fund
operating expenses and capital expenditures, Onconova's anticipated
milestones and future expectations and plans and prospects.
Although Onconova believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Onconova has attempted to identify forward-looking statements by
terminology including “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “should,”
“approximately” or other words that convey uncertainty of future
events or outcomes. These statements are only predictions and
involve known and unknown risks, uncertainties, and other factors,
including Onconova’s need for additional financing and current
plans and future needs to scale back operations if adequate
financing is not obtained, the success and timing of Onconova’s
clinical trials and regulatory approval of protocols, and those
discussed under the heading “Risk Factors” in Onconova’s most
recent Annual Report on Form 10-K and quarterly reports on Form
10-Q.
Any forward-looking statements contained in this
release speak only as of its date. Onconova undertakes no
obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT: Onconova Therapeutics
Benjamin Hoffman, 267-759-3036
bhoffman@onconova.us
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024